Top

Cancer Chemotherapy and Pharmacology

Published in:

01-07-2018 | Clinical Trial Report

Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid^® capsule in healthy Chinese males

Authors: Jin Wang, Lu Qi, Zejuan Wang, Gang Chen, Chen Liu, Ying Liu, Xiaona Liu, Yu Wang, Chunpu Lei, Xinghe Wang

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2018

Abstract

Objective

Lenalidomide is a 4-amino-glutaryl derivative of thalidomide and belongs to a new generation of immunomodulatory agents for the treatment of patients with myelodysplastic syndrome and multiple myeloma. The aim of this study is to evaluate the bioequivalence and safety of a capsule containing 25 mg of a test formulation of lenalidomide and a 25 mg Revlimid^® capsule in healthy, Chinese adult males for good quality anti-cancer medicine with lower costs.

Methods

This was a single-center, randomized, open-label, single-dose, two-period, crossover pharmacokinetic study. Forty-eight healthy, adult Chinese males were administered a test lenalidomide or Revlimid^® capsule, 24 in a fasted and 24 in a fed state, followed by crossover to the other capsule.

Results

Twenty-four subjects in the fasting group and 23 in the postprandial group completed the clinical trial. Subjects administered test lenalidomide and Revlimid^® capsules in the fasting state had a C_max of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC_0−t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC_0−∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively. In the fed state, the subjects had a C_max of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC_0−t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC_0−∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively. Both capsules were well tolerated, with no serious adverse events observed.

Conclusion

According to the criteria for bioequivalence, the test formulation of lenalidomide and Revlimid^® was determined to be bioequivalent.

Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells up regulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961CrossRefPubMed

Lentzsch S, LeBlanc R, Podar K et al (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17:41–44CrossRefPubMed

Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptosis signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525–4530CrossRefPubMed

Ghosh N, Grunwald MR, Fasan O, Bhutani M (2015) Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res 7:105–119CrossRefPubMedPubMedCentral

List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6):549–557CrossRefPubMed

Melchert M, Kale V, List A (2007) The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14(2):123–129CrossRefPubMed

Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10):3458–3464CrossRefPubMedPubMedCentral

Chen N, Lau H, Choudhury S et al (2010) Distribution of lenalidomide into semen of healthy men after multiple oral doses. J Clin Pharmacol 50(7):767–774CrossRefPubMed

Kelly RJ, Smith TJ (2014) Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol 15:e112–e118CrossRefPubMed

10.

Howard DH, Bach PB, Berndt ER et al (2015) Pricing in the market for anticancer drugs. J Econ Perspect 29:139–162CrossRefPubMed

11.

Tefferi A, Kantarjian H, Rajkumar SV et al (2015) In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc 90:996–1000CrossRefPubMedPubMedCentral

12.

Kantarjian HM, Fojo T, Mathisen M et al (2013) Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol 31:3600–3604CrossRefPubMedPubMedCentral

13.

Godman B, Wild C, Haycox A (2017) Patent expiry and costs for anti-cancer medicines for clinical use. Gener Biosimilars Initiat J 6(3):105–106CrossRef

14.

Godman B, Wettermark B, van Woerkom M et al. (2014) Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 5:106PubMedPubMedCentral

15.

Godman B, Bishop I, Finlayson AE et al (2013) Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 13:469–482CrossRefPubMed

16.

Woerkom M, Piepenbrink H, Godman B et al (2012) Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Effect Res 1:527–538CrossRef

17.

Chen N, Kasserra C, Reyes J et al (2012) Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. Cancer Chemother Pharmacol 70(5):717–725CrossRefPubMed

18.

Chen N, Zhou S, Palmisano M (2017) Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet 56(2):139–152CrossRefPubMed

19.

Chen N, Wen L, Lau H et al (2012) Pharmacokinetics, metabolism and excretion of [14-C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 69:789–797CrossRefPubMed

20.

Chen N, Ye Y, Liu L et al (2013) Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol 113(3):179–186CrossRefPubMedPubMedCentral

21.

FDA Contains Nonbinding Recommendations, Draft Guidance on Lenalidomide (2013) https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM326798.pdf

Title: Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males
Authors: Jin Wang
Lu Qi
Zejuan Wang
Gang Chen
Chen Liu
Ying Liu
Xiaona Liu
Yu Wang
Chunpu Lei
Xinghe Wang
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3604-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR–TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations

Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy

Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer

LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer